{
    "Trade/Device Name(s)": [
        "BGM009 Plus Blood Glucose Monitoring System"
    ],
    "Submitter Information": "Apex Bio Technology Corp.",
    "510(k) Number": "K170267",
    "Predicate Device Reference 510(k) Number(s)": [
        "K141036"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NBW",
        "CGA"
    ],
    "Summary Letter Date": "March 9, 2017",
    "Summary Letter Received Date": "February 8, 2017",
    "Submission Date": "January 25, 2017",
    "Regulation Number(s)": [
        "21 CFR 862.1345"
    ],
    "Regulation Name(s)": [
        "Glucose test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Capillary whole blood"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "BGM009 Plus meter"
    ],
    "Method(s)/Technology(ies)": [],
    "Methodologies": [],
    "Submission Type(s)": [
        "Analyzer",
        "Test Strip"
    ],
    "Document Summary": "FDA 510(k) summary for BGM009 Plus Blood Glucose Monitoring System for quantitative measurement of glucose in capillary whole blood using a meter and test strips.",
    "Indications for Use Summary": "Intended for quantitative measurement of glucose in fresh capillary whole blood from fingertip, forearm, or palm; for self-testing by people with diabetes at home to aid in monitoring diabetes control; not for diagnosis, screening, or neonatal use, and for single-patient use only.",
    "fda_folder": "Clinical Chemistry"
}